<info type="ChemicalEntity">alpha-tocopherol</info> and <info type="ChemicalEntity">deferoxamine</info> on <info type="ChemicalEntity">methamphetamine</info>-induced <info type="DiseaseOrPhenotypicFeature">neurotoxicity</info>.

<info type="ChemicalEntity">Methamphetamine</info> (<info type="ChemicalEntity">MA</info>)-induced <info type="DiseaseOrPhenotypicFeature">dopaminergic neurotoxicity</info> is believed to be associated with the increased formation of <info type="ChemicalEntity">free radicals</info>. This study examined the effect of <info type="ChemicalEntity">alpha-tocopherol</info> (<info type="ChemicalEntity">alpha-TC</info>), a scavenger of <info type="ChemicalEntity">reactive oxygen species</info>, and <info type="ChemicalEntity">deferoxamine</info> (<info type="ChemicalEntity">DFO</info>), an iron chelator, on the <info type="ChemicalEntity">MA</info>-induced <info type="DiseaseOrPhenotypicFeature">neurotoxicity</info>. Male <info type="OrganismTaxon">rats</info> were treated with <info type="ChemicalEntity">MA</info> (<info type="ChemicalEntity">10 mg/kg</info>, every <info type="ChemicalEntity">2 h</info> for four injections). The <info type="OrganismTaxon">rat</info> received either <info type="ChemicalEntity">alpha-TC</info> (<info type="ChemicalEntity">20 mg/kg</info>) intraperitoneally for <info type="ChemicalEntity">3 days</info> and <info type="ChemicalEntity">30 min</info> prior to <info type="ChemicalEntity">MA</info> administration or <info type="ChemicalEntity">DFO</info> (<info type="ChemicalEntity">50 mg/kg</info>) subcutaneously <info type="ChemicalEntity">30 min</info> before <info type="ChemicalEntity">MA</info> administration. The concentrations of <info type="GeneOrGeneProduct">dopamine</info> (<info type="ChemicalEntity">DA</info>), <info type="GeneOrGeneProduct">serotonin</info> and their metabolites decreased significantly after <info type="ChemicalEntity">MA</info> administration, which was inhibited by the <info type="ChemicalEntity">alpha-TC</info> and <info type="ChemicalEntity">DFO</info> pretreatment. <info type="ChemicalEntity">alpha-TC</info> and <info type="ChemicalEntity">DFO</info> attenuated the <info type="ChemicalEntity">MA</info>-induced <info type="DiseaseOrPhenotypicFeature">hyperthermia</info> as well as the alterations in the <info type="DiseaseOrPhenotypicFeature">locomotor activity</info>. The level of <info type="ChemicalEntity">lipid peroxidation</info> was higher and the reduced <info type="ChemicalEntity">glutathione</info> concentration was lower in the <info type="OrganismTaxon">MA-treated rats</info>. These changes were significantly attenuated by <info type="ChemicalEntity">alpha-TC</info> and <info type="ChemicalEntity">DFO</info>. This suggests that <info type="ChemicalEntity">alpha-TC</info> and <info type="ChemicalEntity">DFO</info> ameliorate the <info type="ChemicalEntity">MA</info>-induced neuronal damage by decreasing the level of <info type="ChemicalEntity">oxidative stress</info>.